Genta, a biopharmaceutical company, has reported a net loss of $43.08 million or $0.63 per share, for the second quarter of 2009, compared to a net loss of $738.4 million, or $1,004.84 per share, for the second quarter of 2008.
The company has reported net product sales of $69,000, for the second quarter of 2009, compared to $131,000 for same period of 2008.
Genta has reported a net loss of $54.15 million, or $1.24 per share, for the first half of 2009, compared to a net loss of $748.02 million, or $1,060.69 per share, for the same period of 2008.
The company has reported net product sales of $131,000, for the first half of 2009, compared to $248,000 for the same period of 2008.
Raymond Warrell, Jr, CEO of Genta, said: "The last several months have been extraordinarily important. We now believe we will have sufficient financing that will enable release of primary data in our Phase III Genasense trial in melanoma. Certainly, past and recent studies of other drugs in melanoma have proved repeatedly disappointing.
"We believe our biomarker-directed approach, coupled with our uniquely targeted new drug, may transform the treatment of this illness and finally offer meaningful benefit for patients. We expect to release results from our Phase III study within the next three months, which if positive should comprise the basis for worldwide regulatory applications."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
|
Thread abonnieren
ETF-Sparplan